Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189474 | 0.91 | — | — | |
| SCHEMBL12428566 | 0.73 | — | — | |
| SCHEMBL14936408 | 0.72 | NOS1 (0.65) | NOS1FBP1ELANE | |
| SCHEMBL5378534 | 0.70 | — | — | |
| SCHEMBL24062403 | 0.69 | — | — | |
| SCHEMBL881140 | 0.69 | — | — | |
| SCHEMBL1868722 | 0.69 | — | — | |
| SCHEMBL15101304 | 0.69 | — | — | |
| SCHEMBL31340016 | 0.69 | — | — | |
| Praxadine SCHEMBL94070 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8853252-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8648072-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2203061-B1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8580768-B2 | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2640381-A2 | CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | Jenrin Discovery (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130005784-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264797-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2012-10-18 | — | — | US | disclosed |
| US-8217038-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100105751-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2010-04-29 | — | — | US | disclosed |
| US-7666889-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7655685-B2 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | JENRIN DISCOVERY, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009059264-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090118345-A1 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | JENRIN DISCOVERY (US) | 2009-05-07 | — | — | US | disclosed |
| EP-2023920-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | Jenrin Discovery (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7482470-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| WO-2007131219-A2 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS | JENRIN DISCOVERY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | JENRIN DISCOVERY (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005784-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3536/4885FBP1 1087/4885ELANE 4375/4885 |
| US-20090118345-A1 | Cardiometabolic disorders like obesity, diabetes, hypertension and dyslipidemias, 3, 4-diarylpyrazole derivatives; highly selective; limited or no CNS adverse side effects, including mood disorders | CNR2, CNR1, GPR119 | NOS1 2383/4885FBP1 2333/4885ELANE 4785/4885 |
| US-20120264754-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3642/4885FBP1 1352/4885ELANE 4576/4885 |
| US-20070259934-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3536/4885FBP1 1087/4885ELANE 4375/4885 |
| US-20100105751-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3503/4885FBP1 1064/4885ELANE 4410/4885 |
| US-20120264797-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3503/4885FBP1 1064/4885ELANE 4410/4885 |
| US-20090036511-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3536/4885FBP1 1087/4885ELANE 4375/4885 |
| US-20150157605-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES | CNR2, CNR1, GPR119 | NOS1 3503/4885FBP1 1064/4885ELANE 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.